[1] 曾静,范建高.非酒精性脂肪性肝病更名的临床意义[J].临床肝胆病杂志,2020,36(6):1205-1207.
[2] 刘英,崔珊珊,暴素青,等.代谢相关性脂肪性肝病与代谢综合征的研究[J].医学信息,2022,35(1):1-5.
[3] LIM SOO,KIM JIN-WOOK,TARGHER GIOVANNI.Links Between Metabolic Syndrome and Metabolic Dysfunction-Associated Fatty Liver Disease[J].Trends Endocrinol Metab,2021,32(7):500-514.
[4] ESLAM MOHAMMED,SANYAL ARUN J,GEORGE JACOB.MAFLD:A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease[J].Gastroenterology,2020,158(7):1999-2014.
[5] CAUSSY CYRIELLE,AUBIN ADRIEN,LOOMBA ROHIT.The Relationship Between Type 2 Diabetes,NAFLD,and Cardiovascular Risk[J].Current Diabetes Reports,2021,21(5):15.DOI:10.1007/s11892-021-01383-7.
[6] XIAO Jia,WANG Fei,WONG Naikei,et al.Global Liver Disease Burdens and Research Trends:Analysis from a Chinese Aerspective[J].Journal of Hepatology,2019,71(1):212-221.
[7] ZHENG Yan,LEY SYLVIA H,HU FRANK B.Global Aetiology and Epidemiology of Type 2 Diabetes Mellitus and Its Complications[J].Nature Reviews Endocrinology,2018,14(2):88-98.
[8] DAVIS TIMOTHY M E.Diabetes and Metabolic Dysfunction-Associated Fatty Liver Disease[J].Metabolism,2021,123(10):186-188.
[9] ESLAM MOHAMMED,NEWSOME PHILIP N,SARIN SHIV K,et al.A New Definition for Metabolic Dysfunction-Associated Fatty Liver Disease:An International Expert Consensus Statement[J].Journal of Hepatology,2020,73(1):202-209.
[10] MORIOEI MARIO LUCA,TARGHER GIOVANNI,LAPOLLA ANNUNZIATA,et al.Changes in Markers of Hepatic Steatosis and Fibrosis in Patients with Type 2 Diabetes During Treatment with Glucagon-Like Peptide-1 Receptor Agonists.A multicenter Retrospective Longitudinal Study[J].Nutrition Metabolism and Cardiovascular Diseases,2021,31(12):3474-3483.
[11] 刘勤,牛春燕.由“二次打击”到“多重打击”:发病机制的演变带给非酒精性脂肪性肝病的治疗启示[J].世界华人消化杂志,2019,27(19):1171-1178.
[12] MERONI MARICA,MIRIAM LONGO,RUSTICHELLI ALICE,et al.Nutrition and Genetics in NAFLD:The Perfect Binomium[J].International Journal of Molecular Sciences,2020,21(8):2986.DOI:10.3390/ijms21082986.
[13] KUCHAY MOHAMMAD SHAFI,MISHRA SUNIL KUMAR,CHOUDHARY NARENDRA SINGH,et al.Pathophysiological Mechanisms Underlying MAFLD[J].Diabetes Metabolic Syndrome,2020,14(6):1875-1887.
[14] ABDELAEK MANAL F.Nonalcoholic Fatty Liver Disease:Another Leap Forward[J].Nature Reviews Gastroenterology and Hepatology,2021,18(2):85-86.
[15] IPSEN DAVID HJLAND,LYKKESFELDT JENS,TVEDEN-NYBORG PERNILE.Molecular Mechanisms of Hepatic Lipid Accumulation in Non-Alcoholic Fatty Liver Disease[J].Celluar and Mololecular Life Sciences,2018,75(18):3313-3327.
[16] MUNDI MANPREET S,VELAPATI SAKETH,PATEL JANKI,et al.Evolution of NAFLD and Its Management[J].Nutrition in Clinical Practice,2020,35(1):72-84.
[17] 姚诚子,冯巩,宇文思,等.非酒精性脂肪性肝病发生及进展的危险因素[J].临床肝胆病杂志,2020,36(2):433-436.
[18] ESLAM MOHAMMED,GEORGE JACOB.MAFLD:Now is the Time to Capitalize on the Momentum[J].Journal of Hepatology,2021,74(5):1262-1263.
[19] 刘鹏举,马方,楼慧萍,等.脂肪肝危险因素与脂肪肝严重程度的相关因素分析[J].中华肝脏病杂志,2009,17(9):697-698.
[20] 宋素菲.基于代谢组学研究高脂诱导MAFLD模型大鼠血清脂质特征[J].医学研究生学报,2022,35(5):455-459.
[21] USLU ALI UGUR,SEKIN YAHYA,TARHAN GULTEN,et al.Evaluation of Monocyte to High-Density Lipoprotein Cholesterol Ratio in the Presence and Severity of Metabolic Syndrome[J].Clinical and Applied Thrombosis Hemostasia,2018,24(5):828-833.
[22] 杨丽弘,廖鑫,张晗,等.2型糖尿病合并非酒精性脂肪肝肝纤维化与血清25-羟维生素D水平的关系研究[J].中国糖尿病杂志,2018,26(2):117-122.
[23] 李玲.体检者血清25(OH)D与非酒精性脂肪肝的相关性分析[J].内蒙古医学杂志,2021,53(7):776-779.
[24] MATTOVANI ALESSANDRO,DALBNI ANDREA.Treatments for NAFLD:State of Art[J].International Journal of Molecular Sciences,2021,22(5):235-238.
[25] 曾胜澜,王娜,张荣臻,等.代谢相关脂肪性肝病的治疗研究进展[J].中西医结合肝病杂志,2022,32(3):285-288.
[26] RAZA SANA,RJIAK SANGAM,UPADHYAY ADITYA,et al.Current Treatment Paradigms and Emerging Therapies for NAFLD/NASH[J].Frontiers Bioscience,2021,26(2):206-237.
[27] DE OLIVEIRA SOFIA,HOUSERIGT RUTH A,GRAVES ALYSSA L,et al.Metformin Modulates Innate Immune-Mediated Inflammation and Early Progression of NAFLD-Associated Hepatocellular Carcinoma in Zebrafish[J].Journal of Hepatology,2019,70(4):710-721.
[28] ZHAO Xuanye,LIU Yaoji,LIU Jingjin,et al.Therapeutic Effects and Mechanism of Liraglutide on Rats with Type 2 Diabetes and Metabolic-Associated Fatty Liver Disease[J].Endocrine Metabolic Immune Disorder Drug Targets,2022,26(2):110-115.
[29] CIARDULLO STEFANO,PESERGHIN GIANLUCA.Statin Use is Associated with Lower Prevalence of Advanced Liver Fibrosis in Patients with Type 2 Diabetes[J].Metabolism Clinical and Experimental,2021,121(8):154-158.
[30] WANG Wei,XU Ailei,LI Zhengchao,et al.Combination of Probiotics and Salvia Miltiorrhiza Polysaccharide Alleviates Hepatic Steatosis via Gut Microbiota Modulation and Insulin Resistance Improvement in High Fat-Induced NAFLD Mice[J].Diabetes and Metabolism Journal,2020,44(2):336-348.
[31] 范尧夫,曹琳,孙洪平,等.葛根芩连汤治疗2型糖尿病合并非酒精性脂肪性肝病效果的临床研究[J].中国全科医学,2021,24(36):4587-4592.
[32] IKRAMUDDIN SAYEED,KORNER JUDITH,LEE WEI-JEI,et al.Lifestyle Intervention and Medical Management with vs Without Roux-en-Y Gastric Bypass and Control of Hemoglobin A1c,LDL Cholesterol,and Systolic Blood Pressure at 5 Years in the Diabetes Surgery Study[J].The Journal of the American Medical Association,2018,319(3):266-278.
|